Traditionally considered as the master regulator of cytoprotective responses against xenobiotic/electrophilic and oxidative stress [5], the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) was recently found to promote cancer development [6–10], progression [11–14], and therapy resistance [15–22]. This evidence concerns the gene NFE2L2 and cancer.